Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines

Keiichiro Nakamura, Yasutomo Nasu, Atsushi Hongo, Tamaki Matsuo, Junichi Kodama, Shin Ebara, Atsushi Nagai, Fernando Abrzua, Hiromi Kumon, Yuji Hiramatsu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In light of the poor prognosis for ovarian cancer patients, the research continues for innovative and efficacious treatment modalities. Along with surgical and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. However, the biological function of Hepsin expression remains unclear. Apoptotic cell was increasingly common among higher proportions of Hepsin transfectants. We discovered that first-time stable transfectants of Hepsin significantly inhibited cell growth in the monolayer, anchorage-independent cell growth in the soft agar in vitro, and tumorigenicity in vivo in ovarian cancer cell lines. These results demonstrated that Hepsin has a potential therapeutic effect that inhibits through up-regulation of p53-dependent apoptosis and caspase-3, -6, and -7 activations. Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment.

Original languageEnglish
Pages (from-to)393-398
Number of pages6
JournalInternational Journal of Oncology
Volume28
Issue number2
Publication statusPublished - Feb 2006

Fingerprint

Ovarian Neoplasms
Cell Line
Caspase 6
Serine Proteases
Therapeutic Uses
Growth
Caspase 3
Genetic Therapy
Agar
hepsin
Up-Regulation
Therapeutics
Complementary DNA
Clone Cells
Apoptosis
Liver
Research

Keywords

  • Caspase
  • Hepsin
  • Ovarian cancer
  • p53-dependent apoptotic pathway

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakamura, K., Nasu, Y., Hongo, A., Matsuo, T., Kodama, J., Ebara, S., ... Hiramatsu, Y. (2006). Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. International Journal of Oncology, 28(2), 393-398.

Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. / Nakamura, Keiichiro; Nasu, Yasutomo; Hongo, Atsushi; Matsuo, Tamaki; Kodama, Junichi; Ebara, Shin; Nagai, Atsushi; Abrzua, Fernando; Kumon, Hiromi; Hiramatsu, Yuji.

In: International Journal of Oncology, Vol. 28, No. 2, 02.2006, p. 393-398.

Research output: Contribution to journalArticle

Nakamura, K, Nasu, Y, Hongo, A, Matsuo, T, Kodama, J, Ebara, S, Nagai, A, Abrzua, F, Kumon, H & Hiramatsu, Y 2006, 'Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines', International Journal of Oncology, vol. 28, no. 2, pp. 393-398.
Nakamura, Keiichiro ; Nasu, Yasutomo ; Hongo, Atsushi ; Matsuo, Tamaki ; Kodama, Junichi ; Ebara, Shin ; Nagai, Atsushi ; Abrzua, Fernando ; Kumon, Hiromi ; Hiramatsu, Yuji. / Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. In: International Journal of Oncology. 2006 ; Vol. 28, No. 2. pp. 393-398.
@article{c9290523ef45458eb316e4e4b6e6ce10,
title = "Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines",
abstract = "In light of the poor prognosis for ovarian cancer patients, the research continues for innovative and efficacious treatment modalities. Along with surgical and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. However, the biological function of Hepsin expression remains unclear. Apoptotic cell was increasingly common among higher proportions of Hepsin transfectants. We discovered that first-time stable transfectants of Hepsin significantly inhibited cell growth in the monolayer, anchorage-independent cell growth in the soft agar in vitro, and tumorigenicity in vivo in ovarian cancer cell lines. These results demonstrated that Hepsin has a potential therapeutic effect that inhibits through up-regulation of p53-dependent apoptosis and caspase-3, -6, and -7 activations. Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment.",
keywords = "Caspase, Hepsin, Ovarian cancer, p53-dependent apoptotic pathway",
author = "Keiichiro Nakamura and Yasutomo Nasu and Atsushi Hongo and Tamaki Matsuo and Junichi Kodama and Shin Ebara and Atsushi Nagai and Fernando Abrzua and Hiromi Kumon and Yuji Hiramatsu",
year = "2006",
month = "2",
language = "English",
volume = "28",
pages = "393--398",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines

AU - Nakamura, Keiichiro

AU - Nasu, Yasutomo

AU - Hongo, Atsushi

AU - Matsuo, Tamaki

AU - Kodama, Junichi

AU - Ebara, Shin

AU - Nagai, Atsushi

AU - Abrzua, Fernando

AU - Kumon, Hiromi

AU - Hiramatsu, Yuji

PY - 2006/2

Y1 - 2006/2

N2 - In light of the poor prognosis for ovarian cancer patients, the research continues for innovative and efficacious treatment modalities. Along with surgical and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. However, the biological function of Hepsin expression remains unclear. Apoptotic cell was increasingly common among higher proportions of Hepsin transfectants. We discovered that first-time stable transfectants of Hepsin significantly inhibited cell growth in the monolayer, anchorage-independent cell growth in the soft agar in vitro, and tumorigenicity in vivo in ovarian cancer cell lines. These results demonstrated that Hepsin has a potential therapeutic effect that inhibits through up-regulation of p53-dependent apoptosis and caspase-3, -6, and -7 activations. Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment.

AB - In light of the poor prognosis for ovarian cancer patients, the research continues for innovative and efficacious treatment modalities. Along with surgical and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. However, the biological function of Hepsin expression remains unclear. Apoptotic cell was increasingly common among higher proportions of Hepsin transfectants. We discovered that first-time stable transfectants of Hepsin significantly inhibited cell growth in the monolayer, anchorage-independent cell growth in the soft agar in vitro, and tumorigenicity in vivo in ovarian cancer cell lines. These results demonstrated that Hepsin has a potential therapeutic effect that inhibits through up-regulation of p53-dependent apoptosis and caspase-3, -6, and -7 activations. Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment.

KW - Caspase

KW - Hepsin

KW - Ovarian cancer

KW - p53-dependent apoptotic pathway

UR - http://www.scopus.com/inward/record.url?scp=39049181069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049181069&partnerID=8YFLogxK

M3 - Article

C2 - 16391794

AN - SCOPUS:39049181069

VL - 28

SP - 393

EP - 398

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -